Ahmedabad-based Cadila Pharmaceuticals has launched Rosmi F, a fixed-dose combination of Rosuvastatin and Fenofibrate. This innovative therapy has been introduced to address the unmet clinical need in patients suffering from mixed dyslipidemia, a condition marked by elevated low-density lipoprotein (LDL) cholesterol and triglyceride levels that significantly increase cardiovascular risk.
In view of the rising incidence of lifestyle-related disorders such as diabetes, obesity, and cardiovascular diseases, Rosmi F provides a comprehensive lipid management solution that targets multiple lipid parameters simultaneously.
Rosmi F brings together two powerful lipid-lowering agents with complementary mechanisms. Rosuvastatin inhibits HMG-CoA reductase to reduce LDL cholesterol synthesis, while Fenofibrate activates PPAR-α receptors to lower triglycerides and increase HDL-C.
The scientifically proven synergy between rosuvastatin and fenofibrate helps improve lipid profiles more effectively. Together, they provide an integrated, guideline-aligned therapy designed to address elevated LDL-C, high triglycerides, and low HDL-C, common in metabolic syndrome, diabetes, and mixed dyslipidemia.
Evidence from global studies highlights the effectiveness of this combination. A 16-week study demonstrated a 53% reduction in triglycerides with fenofibrate, outperforming niacin extended release and without compromising insulin sensitivity. A 52-week open-label study showed patients achieving both LDL-C and HDL-C targets increasing from 19% at baseline to 50% at week 52 with rosuvastatin and fenofibrate therapy. These results align with leading guidelines, reinforcing the tablet’s clinical relevance and suitability.
